Form 4: Adicet Bio Director Katie Peng Receives Equity Grants Valued at $0.78 Per Share

Adicet Bio, Inc. Director Katie Peng has reported the acquisition of 5,900 Restricted Stock Units (RSUs) and 26,400 stock options, aligning her interests with the company's long-term performance.

Summary

• Katie Peng, a Director at Adicet Bio, Inc. (ACET), reported transactions on June 11, 2025.
• She acquired 5,900 shares of Common Stock through Restricted Stock Units (RSUs) at a price of $0 per share.
• These RSUs represent a contingent right to receive one share of Common Stock each and will vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders, subject to her continued service.
• Following this transaction, Ms. Peng beneficially owns 11,800 shares of Common Stock directly.
• Additionally, she acquired 26,400 stock options with an exercise price of $0.78 per share.
• These stock options also vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders, subject to her continued service.
• The options have an expiration date of June 10, 2035.
• Following this transaction, Ms. Peng beneficially owns 26,400 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates continued alignment of a director's interests with the company's performance through equity compensation, which is a standard and generally favorable practice.

Positives

• The equity grants (RSUs and stock options) align the Director's financial interests with the long-term performance and shareholder value of Adicet Bio, Inc.
• The grants are a standard form of compensation for board members, indicating continued commitment and incentivization for the Director's service.

Risks

• The vesting of both the Restricted Stock Units and stock options is contingent upon Katie Peng's continued service on Adicet Bio's board of directors, meaning the benefits are not guaranteed if her service ceases.

Future Outlook

The equity grants are designed to incentivize the Director's continued service and align her interests with the company's long-term performance, with vesting contingent on her remaining on the board until the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.

Management Comments

• The filing indicates that the Restricted Stock Units (RSUs) may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, specifically equity compensation for a director, which is a common practice across publicly traded companies to attract and retain talent and align management/board interests with shareholders.

Corporate Governance

Related Party Transactions

• The equity grants to Director Katie Peng constitute a related party transaction, as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting and exercise of equity, but also benefit from increased alignment of director's interests with long-term company performance.
• Director (Katie Peng): Receives significant equity compensation, incentivizing continued service and performance.

Next Steps

• The Restricted Stock Units and stock options will vest based on the specified conditions: the earlier of the first anniversary of the grant date (June 11, 2026) or the date of the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Adicet Bio, ACET, SEC Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, RSU, Stock Options, Equity Grant, Corporate Governance